KURA ONCOLOGY INC. - COMMON STOCK

Kura Oncology to Participate in Stifel Targeted Oncology Forum

10 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 أبريل 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

06 مارس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 مارس 2024 17:00:00 بحسب Nasdaq GlobeNewswire

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

27 فبراير 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

26 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Kura Oncology to Participate in Three Upcoming Investor Conferences

22 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

20 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 فبراير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

30 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Kura Oncology Announces Oversubscribed $150 Million Private Placement

24 يناير 2024 07:00:57 بحسب Nasdaq GlobeNewswire

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

08 ديسمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

28 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Kura Oncology Reports Third Quarter 2023 Financial Results

02 نوفمبر 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

02 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Kura Oncology to Participate in Three Upcoming Investor Conferences

30 أكتوبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Kura Oncology to Report Third Quarter 2023 Financial Results

26 أكتوبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

19 أكتوبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

17 أكتوبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04 أكتوبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire